Evidence map›Paper›PMID 34173542›Full record

ReviewEuropean urology open science2020

Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists.

Zachary Dovey, Nihal Mohamed, Yasmine Gharib, Parita Ratnani, Nada Hammouda, Sujit S Nair, Dimple Chakravarty, Stanislaw Sobotka, Anna Lantz, Peter Wiklund and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in European urology open science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. The Impact of COVID-19 Disease on Urology Practice.Surgery journal (New York, N.Y.) · 2021
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Zachary DoveyDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nihal MohamedDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yasmine GharibDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Parita RatnaniDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nada HammoudaDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sujit S NairDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dimple ChakravartyDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stanislaw SobotkaDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Anna LantzDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden.
Peter WiklundDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Natasha KyprianouDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ash TewariDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Icahn School of Medicine at Mount Sinai · USKarolinska Institutet · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in a global health emergency, the like of which has never been seen before. Prostate cancer (PCa) services across the globe have been on hold due to changing medical and surgical priorities. There is also epidemiological evidence that PCa patients have increased incidence and mortality from SARS-CoV-2 infection due to gender differences, age, and higher propensity for risk factors (eg, respiratory disease, obesity, hypertension, and smoking status).

objectiveTo contribute to the emerging body of knowledge on the risks of SARS-CoV-2 infection to PCa patients and, in the face of PCa treatment delays, provide evidence-based recommendations for ongoing management of specific PCa patient groups. EVIDENCE ACQUISITION: A literature search was performed using all sources (MEDLINE, EMBASE, ScienceDirect, Cochrane Libraries, and Web of Science) as well as the media to harness emerging data on the SARS-CoV-2 pandemic and its influence on PCa. Eligibility criteria were originality of data and relevance to PCa management. The authors note that during these unprecedented times, retrospective data are constantly being updated from multiple sources globally. EVIDENCE SYNTHESIS: A total of 72 articles and data sources were found initially. Owing to repetition, lack of originality, or nonrelevance, six articles were rejected, leaving 23 retrospective studies, seven basic science research articles, 15 societal and journal guidelines, and 21 epidemiological data sources, from countries at different stages of SARS-CoV-2 pandemic. These were analyzed qualitatively to produce evidence-based guidelines for the management of PCa patients at different stages of the patient journey, with strategies to reduce the risk of viral spread.

conclusionsPCa patients may have an increased risk of SARS-CoV-2 infection as well as morbidity and mortality if infected. Once appropriately triaged, and to reduce viral spread, PCa patients can have surveillance by telemedicine, and institute lifestyle changes and social quarantining measures. If risk stratification suggests that treatment should be planned, androgen deprivation therapy can be started, or potentially surgery or radiation therapy is possible on a case-by-case basis. PATIENT SUMMARY: Prostate cancer patients can be followed up remotely until the severe acute respiratory syndrome coronavirus 2 pandemic resolves, but higher-risk cases may have treatment expedited to limit any negative impact on prostate cancer outcomes.

Indexed as

COVID-19 pandemicInfection risksProstate cancerTreatment delaysTriage

Identifiers

PMID34173542
PMCPMC7296308
OpenAlexW3035206230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.